(THC) Tenet Healthcare - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US88033G4073
Hospital Care, Ambulatory Surgery, Urgent Care, Imaging Centers
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 37.6% |
| Value at Risk 5%th | 59.3% |
| Relative Tail Risk | -4.30% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.06 |
| Alpha | 34.04 |
| CAGR/Max DD | 1.87 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.466 |
| Beta | 0.971 |
| Beta Downside | 1.195 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.90% |
| Mean DD | 8.34% |
| Median DD | 4.46% |
Description: THC Tenet Healthcare October 16, 2025
Tenet Healthcare Corp. (NYSE: THC) is a diversified U.S. health-services operator that runs two primary segments-Hospital Operations & Services and Ambulatory Care-covering acute-care hospitals, specialty surgery centers, urgent-care and micro-hospital facilities, plus a broad portfolio of clinical services ranging from cardiothoracic surgery to tele-medicine.
Key operating metrics (FY 2023) show revenue of roughly $15.3 billion, an adjusted EBITDA margin near 8 % and an average hospital occupancy rate of about 71 %, reflecting modest demand growth amid a tightening labor market. The business is especially sensitive to Medicare-DRG reimbursement trends, regional labor-cost inflation, and the broader industry shift toward outpatient and tele-health delivery models, which together drive both volume and margin dynamics.
For a deeper, data-driven look at THC’s valuation multiples and peer benchmarks, you may find ValueRay’s analytical tools worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.35b TTM) > 0 and > 6% of Revenue (6% = 1.25b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -3.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 15.58% (prev 15.36%; Δ 0.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 2.48b > Net Income 1.35b (YES >=105%, WARN >=100%) |
| Net Debt (10.21b) to EBITDA (4.42b) ratio: 2.31 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (88.6m) change vs 12m ago -8.32% (target <= -2.0% for YES) |
| Gross Margin 55.93% (prev 39.55%; Δ 16.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 70.95% (prev 71.40%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.39 (EBITDA TTM 4.42b / Interest Expense TTM 819.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.19
| (A) 0.11 = (Total Current Assets 7.81b - Total Current Liabilities 4.56b) / Total Assets 29.42b |
| (B) 0.14 = Retained Earnings (Balance) 4.04b / Total Assets 29.42b |
| (C) 0.12 = EBIT TTM 3.59b / Avg Total Assets 29.39b |
| (D) 0.19 = Book Value of Equity 3.88b / Total Liabilities 20.72b |
| Total Rating: 2.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.32
| 1. Piotroski 6.50pt |
| 2. FCF Yield 5.15% |
| 3. FCF Margin 7.20% |
| 4. Debt/Equity 3.29 |
| 5. Debt/Ebitda 2.31 |
| 6. ROIC - WACC (= 10.80)% |
| 7. RoE 33.61% |
| 8. Rev. Trend 79.27% |
| 9. EPS Trend 65.89% |
What is the price of THC shares?
As of December 06, 2025, the stock is trading at USD 210.00 with a total of 571,744 shares traded.
Over the past week, the price has changed by -3.15%, over one month by +0.66%, over three months by +7.04% and over the past year by +51.19%.
Over the past week, the price has changed by -3.15%, over one month by +0.66%, over three months by +7.04% and over the past year by +51.19%.
Is THC a buy, sell or hold?
Tenet Healthcare has received a consensus analysts rating of 4.32.
Therefore, it is recommended to buy THC.
- Strong Buy: 12
- Buy: 5
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the THC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 233.4 | 11.2% |
| Analysts Target Price | 233.4 | 11.2% |
| ValueRay Target Price | 319.8 | 52.3% |
THC Fundamental Data Overview December 03, 2025
Market Cap USD = 18.98b (18.98b USD * 1.0 USD.USD)
P/E Trailing = 14.605
P/E Forward = 13.7552
P/S = 0.9106
P/B = 4.7102
P/EG = 0.8537
Beta = 1.447
Revenue TTM = 20.86b USD
EBIT TTM = 3.59b USD
EBITDA TTM = 4.42b USD
Long Term Debt = 13.10b USD (from longTermDebt, last quarter)
Short Term Debt = 85.0m USD (from shortTermDebt, last quarter)
Debt = 13.19b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.21b USD (from netDebt column, last quarter)
Enterprise Value = 29.19b USD (18.98b + Debt 13.19b - CCE 2.98b)
Interest Coverage Ratio = 4.39 (Ebit TTM 3.59b / Interest Expense TTM 819.0m)
FCF Yield = 5.15% (FCF TTM 1.50b / Enterprise Value 29.19b)
FCF Margin = 7.20% (FCF TTM 1.50b / Revenue TTM 20.86b)
Net Margin = 6.49% (Net Income TTM 1.35b / Revenue TTM 20.86b)
Gross Margin = 55.93% ((Revenue TTM 20.86b - Cost of Revenue TTM 9.19b) / Revenue TTM)
Gross Margin QoQ = 58.33% (prev 82.32%)
Tobins Q-Ratio = 0.99 (Enterprise Value 29.19b / Total Assets 29.42b)
Interest Expense / Debt = 1.56% (Interest Expense 206.0m / Debt 13.19b)
Taxrate = 18.68% (133.0m / 712.0m)
NOPAT = 2.92b (EBIT 3.59b * (1 - 18.68%))
Current Ratio = 1.71 (Total Current Assets 7.81b / Total Current Liabilities 4.56b)
Debt / Equity = 3.29 (Debt 13.19b / totalStockholderEquity, last quarter 4.01b)
Debt / EBITDA = 2.31 (Net Debt 10.21b / EBITDA 4.42b)
Debt / FCF = 6.80 (Net Debt 10.21b / FCF TTM 1.50b)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.60% (Net Income 1.35b / Total Assets 29.42b)
RoE = 33.61% (Net Income TTM 1.35b / Total Stockholder Equity 4.03b)
RoCE = 20.97% (EBIT 3.59b / Capital Employed (Equity 4.03b + L.T.Debt 13.10b))
RoIC = 16.98% (NOPAT 2.92b / Invested Capital 17.20b)
WACC = 6.18% (E(18.98b)/V(32.17b) * Re(9.59%) + D(13.19b)/V(32.17b) * Rd(1.56%) * (1-Tc(0.19)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -7.77%
[DCF Debug] Terminal Value 76.58% ; FCFE base≈1.86b ; Y1≈2.29b ; Y5≈3.91b
Fair Price DCF = 574.7 (DCF Value 50.50b / Shares Outstanding 87.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 65.89 | EPS CAGR: 8.77% | SUE: 0.67 | # QB: 0
Revenue Correlation: 79.27 | Revenue CAGR: 2.30% | SUE: 0.24 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.42 | Chg30d=+0.093 | Revisions Net=+3 | Analysts=16
EPS next Year (2026-12-31): EPS=16.45 | Chg30d=+0.333 | Revisions Net=+10 | Growth EPS=+2.1% | Growth Revenue=+4.3%
P/E Trailing = 14.605
P/E Forward = 13.7552
P/S = 0.9106
P/B = 4.7102
P/EG = 0.8537
Beta = 1.447
Revenue TTM = 20.86b USD
EBIT TTM = 3.59b USD
EBITDA TTM = 4.42b USD
Long Term Debt = 13.10b USD (from longTermDebt, last quarter)
Short Term Debt = 85.0m USD (from shortTermDebt, last quarter)
Debt = 13.19b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.21b USD (from netDebt column, last quarter)
Enterprise Value = 29.19b USD (18.98b + Debt 13.19b - CCE 2.98b)
Interest Coverage Ratio = 4.39 (Ebit TTM 3.59b / Interest Expense TTM 819.0m)
FCF Yield = 5.15% (FCF TTM 1.50b / Enterprise Value 29.19b)
FCF Margin = 7.20% (FCF TTM 1.50b / Revenue TTM 20.86b)
Net Margin = 6.49% (Net Income TTM 1.35b / Revenue TTM 20.86b)
Gross Margin = 55.93% ((Revenue TTM 20.86b - Cost of Revenue TTM 9.19b) / Revenue TTM)
Gross Margin QoQ = 58.33% (prev 82.32%)
Tobins Q-Ratio = 0.99 (Enterprise Value 29.19b / Total Assets 29.42b)
Interest Expense / Debt = 1.56% (Interest Expense 206.0m / Debt 13.19b)
Taxrate = 18.68% (133.0m / 712.0m)
NOPAT = 2.92b (EBIT 3.59b * (1 - 18.68%))
Current Ratio = 1.71 (Total Current Assets 7.81b / Total Current Liabilities 4.56b)
Debt / Equity = 3.29 (Debt 13.19b / totalStockholderEquity, last quarter 4.01b)
Debt / EBITDA = 2.31 (Net Debt 10.21b / EBITDA 4.42b)
Debt / FCF = 6.80 (Net Debt 10.21b / FCF TTM 1.50b)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.60% (Net Income 1.35b / Total Assets 29.42b)
RoE = 33.61% (Net Income TTM 1.35b / Total Stockholder Equity 4.03b)
RoCE = 20.97% (EBIT 3.59b / Capital Employed (Equity 4.03b + L.T.Debt 13.10b))
RoIC = 16.98% (NOPAT 2.92b / Invested Capital 17.20b)
WACC = 6.18% (E(18.98b)/V(32.17b) * Re(9.59%) + D(13.19b)/V(32.17b) * Rd(1.56%) * (1-Tc(0.19)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -7.77%
[DCF Debug] Terminal Value 76.58% ; FCFE base≈1.86b ; Y1≈2.29b ; Y5≈3.91b
Fair Price DCF = 574.7 (DCF Value 50.50b / Shares Outstanding 87.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 65.89 | EPS CAGR: 8.77% | SUE: 0.67 | # QB: 0
Revenue Correlation: 79.27 | Revenue CAGR: 2.30% | SUE: 0.24 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.42 | Chg30d=+0.093 | Revisions Net=+3 | Analysts=16
EPS next Year (2026-12-31): EPS=16.45 | Chg30d=+0.333 | Revisions Net=+10 | Growth EPS=+2.1% | Growth Revenue=+4.3%
Additional Sources for THC Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle